Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals
- Registration Number
- NCT02238262
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The aim of the observational study was to supplement the data on efficacy, safety and tolerability of telmisartan under daily conditions in hospitals
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2318
Inclusion Criteria
- Patients with diagnosis of essential hypertension
- Minimum age of 18 years
Exclusion Criteria
- NA
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description essential hypertension patients Telmisartan -
- Primary Outcome Measures
Name Time Method Change in clinic blood pressure up to 14 days Number of patients with adverse drug reactions up to 14 days
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of telmisartan in essential hypertension management?
How does telmisartan compare to other ARBs in treating essential hypertension in hospitals?
Which biomarkers correlate with telmisartan efficacy in essential hypertension patients?
What adverse events are associated with telmisartan therapy in hospitalized patients?
Are there combination therapies involving telmisartan for resistant hypertension treatment?